Michael Lewash

Michael Lewash

Auto-generated profile, based on publicly available information

Michael Lewash

PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2025 in Trends in Pharmacological Sciences
Verified
Journal Article
Open access
MLMichael Lewash
Michael Lewash
EKEvi Kostenis
Evi Kostenis
CMChrista Müller
Christa Müller
The orphan G protein-coupled receptor (GPCR) GPR17, whose physiological agonist remains unknown, has emerged as a promising drug target for multiple sclerosis (MS). Blockade of the receptor enables remyelination and may offer a novel therapeutic strategy for MS. Only recently, potent and selective tool compounds for GPR17 have become available, and patents on antagonists have surged, leading to the first clinical candidate, the GPR17 antagonist PTD802, which is to be developed for MS therapy. This may pave the way for further clinical studies exploring additional indications, such as neurodegenerative diseases. The newly determined cryo-electron microscopy (cryo-EM) structure of GPR17 is expected to facilitate future structure-based drug design efforts. This review presents and discusses these latest developments, providing a timely and comprehensive overview to guide future research in the field.

1 November 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NBNader M. Boshta
Nader M. Boshta
MLMichael Lewash
Michael Lewash
MKMeryem Köse
Meryem Köse
VNVigneshwaran Namasivayam
Vigneshwaran Namasivayam
SSSoumya Sarkar
Soumya Sarkar
CMChrista Müller
Christa Müller